5,11-dihydrodibenzo[b,e][1,4]thiazepine | 3048-78-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并硫氮卓类
• 英文名称: 5,11-dihydrodibenzo[b,e][1,4]thiazepine
• 英文别名: 6,11-Dihydrobenzo[c][1,5]benzothiazepine
• CAS: 3048-78-0
• 化学式: C₁₃H₁₁NS
• 分子量: 213.303
• InChiKey: JVWKQCOSIPNOKD-UHFFFAOYSA-N

物化性质

• 熔点：
  120-121 °C(Solv: ethanol, 99M (64-17-5))
• 沸点：
  200-220 °C(Press: 0.4 Torr)
• 密度：
  1.189±0.06 g/cm3(Predicted)
• 溶解度：
  6.8 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5,11-dihydrodibenzo[b,e][1,4]thiazepine 生成 diethyl-[2-(5-methyl-5,11-dihydro-dibenzo[b,e][1,4]thiazepin-11-yl)-ethyl]-amine
  参考文献：
  名称：

  11-(2'-Dimethylaminoethyl)-5-methyl-5,11-dihydrodibenzo[b,e][1,4]thiazepin 及相关化合物的合成。神经药物和精神药物

  摘要：

  描述了 11-(2'-二甲氨基乙基)-5-甲基-5,11-二氢二苯并[b,e][1,4] thiazepin 和相关化合物的合成。11-Lithiolated 5-methyl-5,11-dihydrodibenzo[b,e][1,4]thiazepin (18) 被用作制备这些化合物的关键中间体。

  DOI：

  10.1246/bcsj.48.2323
• 作为产物：
  描述：

  双(2-硝基苯基)二硫化物 在 bis(dibenzylideneacetone)-palladium⁽⁰⁾ sodium sulfide 、 三叔丁基膦 、 potassium carbonate 、 sodium t-butanolate 作用下， 以 水 、 甲苯 为溶剂， 反应 3.0h， 生成 5,11-dihydrodibenzo[b,e][1,4]thiazepine
  参考文献：
  名称：

  An Efficient Assembly of Heterobenzazepine Ring Systems Utilizing an Intramolecular Palladium-Catalyzed Cycloamination

  摘要：

  Azaheterocyclic compounds are interesting and medicinally relevant targets. Herein we disclose an improved synthesis into the oxazepine and thiazepine ring systems. The key step in the synthesis exploits recent advancements in the palladium-catalyzed amination reaction, which was utilized to form the seven-membered rings. General conditions for this reaction were Pd(2)dba(3), P(t-BU)(3), NaO-t-Bu alone or with K2CO3, in toluene. The scope of the reaction was investigated, and has been shown to be effective on a variety of substrates as illustrated.

  DOI：

  10.1021/jo026546g

文献信息

• A modular CuI-L-proline catalyzed one-pot route for the rapid access of constrained and privileged hetero-atom-linked medium-sized ring systems
  作者：Vunnam Srinivasulu、Kim D. Janda、Imad A. Abu-Yousef、Matthew John O'Connor、Taleb H. Al-Tel

  DOI：10.1016/j.tet.2017.02.061

  日期：2017.4

  4]diazepin, benzo[e]pyrrolo[1,2-a][1,4]diazocin, benzo[e]pyrido[1,2-a][1,4]diazocinones, dibenzo[b,f][1,5]diazoninones, dihydrodibenzo[b,e][1,4]thiazepine, dibenzo[b,e][1,4]thiazocine and benzo[6,7][1,4]diazepino[1,2-a]indole. Moreover, the synthetic procedures described herein, allows rapid entries to synthetically challenging medium-sized heterocyclic systems with good overall yields.

  开发了一种有效的CuI-L-脯氨酸催化的一锅合成方法，以生成一系列骨架多样的杂环系统，大小范围为6至9。该设计策略的显着特征是其使用S N 2反应的模块化合成效用。随后是微波辅助的CuI-L-脯氨酸杂芳基化反应，该化合物已获得一系列杂环骨架的访问权，其中包括：苯并[e]吡咯并[1,2-a] [1,4]二氮杂，苯并[e]吡咯并[1,2-a] [1,4]二唑啉，苯并[e]吡啶基[1,2-a] [1,4]重氮酮，二苯并[b，f] [1,5]重氮酮，二氢二苯并[b， e] [1,4] thiazepine，二苯并[b，e] [1,4]噻唑嗪和苯并[6,7] [1,4]二氮杂p [1,2- a]吲哚。此外，本文所述的合成方法允许以良好的总收率快速进入具有合成挑战性的中型杂环系统。
• [EN] COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS<br/>[FR] COMPOSÉS ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE BACE1
  申请人：ALLGENESIS BIOTHERAPEUTICS INC

  公开号：WO2016172255A1

  公开（公告）日：2016-10-27

  The present invention relates to compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein X, Y, Z, Q, W, m, u, ring (A), R2, R3, R4, R5 and R6, are as defined in the specification and claims. The present invention provides a pharmaceutical composition containing the compounds of Formula (I) and a therapeutic method of treating and/or preventing Downs syndrome, β-amyloid angiopathy, disorders associated with cognitive impairment, Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegenerative diseases, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, Alzheimer's disease and/or Down syndrome, age-related macular degeneration (AMD), glaucoma, olfactory function impairment, traumatic brain injury, progressive muscle diseases, Type II diabetes mellitus and cardiovascular diseases (stroke).

  本发明涉及式（I）的化合物或其立体异构体、互变异构体、或其药学上可接受的盐或溶剂，其中X、Y、Z、Q、W、m、u、环（A）、R2、R3、R4、R5和R6如规范和权利要求中所定义。本发明提供了含有式（I）化合物的药物组合物，以及治疗和/或预防唐氏综合征、β-淀粉样血管病、与认知损伤相关的疾病、阿尔茨海默病、记忆丧失、与阿尔茨海默病相关的注意力缺陷症状、神经退行性疾病、早老性痴呆、老年性痴呆和与帕金森病、阿尔茨海默病和/或唐氏综合征相关的痴呆、年龄相关性黄斑变性（AMD）、青光眼、嗅觉功能障碍、创伤性脑损伤、进行性肌肉疾病、2型糖尿病和心血管疾病（中风）的治疗方法。
• Oxazepine derivatives and medicine containing the same
  申请人：Ajinomoto Co., Inc.

  公开号：US20020099047A1

  公开（公告）日：2002-07-25

  The present invention provides (R)-5,11-dihydro-5-[1-(4-methoxyphenethyl)piperidine-2-ylmethyl]dibenzo[b,e][1,4]oxazepine, (R)-5,11-dihydro-5-[1-(4-dimethylaminophenethyl)piperidine-2-ylmethyl]dibenzo[b,e][1,4]oxazepine, compounds analogous to them and pharmaceutical compositions containing such a compound. These compounds are useful for treating or preventing abnormal motor functions of gastrointestinal tracts, particularly irritable bowel syndrome.

  本发明提供(R)-5,11-二氢-5-[1-(4-甲氧基苯乙基)哌啶-2-基甲基]二苯并[b,e][1,4]噁唑啉，(R)-5,11-二氢-5-[1-(4-二甲氨基苯乙基)哌啶-2-基甲基]二苯并[b,e][1,4]噁唑，以及类似它们的化合物和含有这种化合物的药物组合物。这些化合物可用于治疗或预防胃肠道异常运动功能，特别是肠易激综合征。
• 5,11-dihydrodibenzo[b,e][1,4]-thiazepines useful as gastro intestinal
  申请人：Pfizer Inc.

  公开号：US05071844A1

  公开（公告）日：1991-12-10

  The invention provides compounds of the formula: ##STR1## wherein k is 1, 2 or 3; m is 1, 2 or 3; n is 1, 2 or 3; p is 0, 1 or 2; X is O, S or a direct link, with the proviso that when X is O or S, n is 2 or 3; R.sup.1 is H or C.sub.1-C.sub.4 alkyl; and R.sup.2 is an optionally substituted phenyl or heteroaryl group; and pharmaceutically acceptable salts thereof. These compounds are useful for the treatment of motility disorders, particularly those of the gut such as irritable bowel syndrome.

  该发明提供了以下式化合物：##STR1## 其中k为1、2或3；m为1、2或3；n为1、2或3；p为0、1或2；X为O、S或直链，但当X为O或S时，n为2或3；R.sup.1为H或C.sub.1-C.sub.4烷基；R.sup.2为可选择取代的苯基或杂环基团；以及其药学上可接受的盐。这些化合物可用于治疗运动障碍，特别是肠道运动障碍，如肠易激综合征。
• [EN] SULFENAMIDE COMPOUNDS FOR PHOTOTHERAPY<br/>[FR] COMPOSÉS DE SULFÉNAMIDE DESTINÉS À UNE PHOTOTHÉRAPIE
  申请人：MALLINCKRODT INC

  公开号：WO2011060113A1

  公开（公告）日：2011-05-19

  The invention relates generally to optical agents for biomedical applications, including phototherapy. Provided are sulfenamide compounds having an acyclic S-N bond with at least one aromatic and/or heterocyclic aromatic group providing phototherapeutic agents, including Type 1 phototherapeutic agents. Optical agents of the invention enable a versatile phototherapy platform for treatment of a range of pathological conditions, including the treatment of cancers, stensosis and inflammation. The invention further provides preparations and formulations comprising the sulfenamide optical agents and related methods of making and using sulfenamide optical agents in an in vivo or ex vivo biomedical procedure.

  本发明涉及用于生物医学应用，包括光疗的光学试剂。提供了具有无环S-N键的磺酰胺化合物，其中至少有一个芳香和/或杂环芳香基团，提供光疗试剂，包括1型光疗试剂。本发明的光学试剂为治疗一系列病理状况提供了多功能光疗平台，包括治疗癌症、狭窄和炎症。本发明还提供了包含磺酰胺光学试剂的制剂和配方以及相关的制备和使用磺酰胺光学试剂在体内或体外生物医学程序中的方法。